Interchangeability of CSF and PET to identify Alzheimer's disease pathology
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · 2026-04 · 18 (2)
DOI: 10.1002/dad2.70288 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, online erschienen am 12.05.2026. Verfasst von Samantha C Burnham und 12 weiteren Autor:innen. Beteiligte Einrichtung: Eli Lilly and Company Indianapolis Indiana USA. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS, Eli Lilly and Company.
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION Establishing interchangeability between cerebrospinal fluid (CSF) and positron emission tomography (PET) for patient identification may improve access to Alzheimer's disease (AD) therapies. METHODS Alzheimer's Disease Neuroimaging Initiative participants with mild cognitive impairment or AD dementia and available CSF, florbetapir PET, and/or flortaucipir PET were included. The interchangeability of CSF (per label threshold/method) and PET was evaluated for patient identification. RESULTS Fujirebio Lumipulse amyloid beta (Aβ) 42/Aβ40 ( N = 288) and Roche Elecsys phosphorylated tau 181 (P‐tau181)/Aβ42 ( N = 251) Conformité Européene (CE)‐marked CSF assays were in high agreement with and non‐inferior to florbetapir PET for identifying patients with AD pathology. High agreement was observed between Roche Elecsys CSF P‐tau181/Aβ42 ( N = 127) and an early (temporal) flortaucipir PET stratification. DISCUSSION CSF assays were interchangeable with amyloid PET to identify patients with AD pathology and were in high agreement with elevated early temporal flortaucipir PET. CSF biomarkers may be used as a robust alternative to PET, potentially increasing access to AD diagnosis and disease‐modifying treatments.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Eli Lilly and Company Indianapolis Indiana USA.
- Eli Lilly and Company Sesto Fiorentino Italy.
- Hospital of the University of Pennsylvania Philadelphia Pennsylvania USA.
- Fujirebio Diagnostics Inc. Malvern Pennsylvania USA.
- Eli Lilly and Company Zurich Switzerland.
ORCID-Profile: Samantha C Burnham
Förderung
- NIA NIH HHS
- Eli Lilly and Company
Zitieren
APA
Burnham, S. C., Arora, A. K., Iaccarino, L., Kennedy, I., Kotari, V., Wijayawardana, S. R., Shaw, L. M., Benina, N., Lu, M., Pontecorvo, M. J., Quevenco, F. C., Wang, J., & Alzheimer's Disease Neuroimaging Initiative (2026). Interchangeability of CSF and PET to identify Alzheimer's disease pathology. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 18(2). https://doi.org/10.1002/dad2.70288
Vancouver
Burnham SC, Arora AK, Iaccarino L, Kennedy I, Kotari V, Wijayawardana SR, et al. Interchangeability of CSF and PET to identify Alzheimer's disease pathology. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 2026;18(2). doi:10.1002/dad2.70288
BibTeX
@article{Burnham2026,
author = {Burnham, Samantha C and Arora, Anupa K and Iaccarino, Leonardo and Kennedy, Ian and Kotari, Vikas and Wijayawardana, Sameera R and Shaw, Leslie M and Benina, Natalya and Lu, Ming and Pontecorvo, Michael J and Quevenco, Frances-Catherine and Wang, Jian and Alzheimer's Disease Neuroimaging Initiative, Alzheimer's Disease Neuroimaging Initiative},
title = {Interchangeability of CSF and PET to identify Alzheimer's disease pathology},
journal = {Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring},
year = {2026},
volume = {18},
number = {2},
doi = {10.1002/dad2.70288}
}
EUVIMED